(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...